Related Experiment Video
Updated: Jul 15, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Development of a heterologous, multigenotype vaccine against hepatitis C virus infection
J Encke1, W Radunz, C Eisenbach
1University of Heidelberg, Heidelberg, Germany. jens_encke@med.uni-heidelberg.de
Insights
Developing a multigenotype hepatitis C virus (HCV) vaccine using plasmid DNA demonstrated cross-reactive immune potential. This approach may overcome viral immune escape in future HCV vaccine strategies.
Area of Science:
- Virology
- Immunology
- Vaccine Development
Background:
- Hepatitis C virus (HCV) exhibits significant genetic diversity, contributing to immune escape and chronic infection.
- Current HCV vaccine strategies often overlook viral heterogeneity, hindering efficacy.
- Challenges in HCV vaccine development include lack of protective immunity in animal models and reported reinfections in humans.
Purpose of the Study:
- To evaluate a novel 'multigenotype' or 'library' DNA vaccine approach against HCV.
- To characterize the humoral and cellular immune responses to an envelope 1 (E1) plasmid vaccine in a mouse model.
Main Methods:
- Constructed plasmid DNA vaccines encoding either a defined set of HCV genotypes/subtypes (defined vaccine, DV) or genetic information from 20 patients (library vaccine, LV).
- Administered E1 plasmid vaccines to a mouse model.
- Assessed humoral immune responses using ELISA and cellular immune responses via T-cell proliferation and ELISPOT assays.
Main Results:
- Immunized animals showed robust humoral and cellular immune responses, particularly against genotype 1, as expected.
- Not all animals immunized with genotype 1 antigen recognized it, suggesting epitope immunogenicity loss due to amino acid changes.
- Sera from mice immunized with genotype 4 and 5 antigens showed reactivity against the E1 protein.
Conclusions:
- The developed DV and LV vaccines demonstrated immune reactivity, indicating cross-reactive potential.
- This strategy, leveraging HCV's genetic heterogeneity, has significant implications for developing effective HCV vaccines.
- The approach may offer a way to overcome viral immune escape in both prophylactic and therapeutic settings for HCV.
Background:
Unquestionably viral diversity and genetic heterogeneity in hepatitis C virus (HCV) infection and other viral diseases play an essential role in viral immune escape and the development of chronicity. Despite this knowledge most vaccine approaches against HCV have excluded this important issue. Moreover the feasibility of developing an effective HCV vaccine has been questioned, mainly because prophylactic immunity against HCV cannot be achieved in chimpanzees by either vaccination or previous HCV infection, and reinfection in men has been reported, most likely due to genetic shift and immune escape. To analyse and characterize a new technique of a 'multigenotype'- and/or 'library'-vaccine, we established an envelope 1 (E1) plasmid vaccine against HCV and characterized humoral and cellular immune responses after vaccination in a mouse model.
Material And Methods:
Normally genetic information of one or two target proteins is cloned into a DNA-vaccine. In our approach we cloned a defined number of different genotypes and subtypes (defined vaccine, DV) or the genetic information from 20 patients (undefined) into a plasmid (library vaccine, LV).
Results:
As expected, immunized animals showed both stronger humoral (ELISA) and cellular (T-cell proliferation, ELISPOT) immune responses against genotype 1, since the stimulating antigen was genotype 1 derived. However, not all genotype 1 immunized animals recognized this viral antigen leading to the assumption that some epitopes lost their immunogenicity through a change in the amino acid sequence. Interestingly, some of the genotype 4 and 5 immunized mice sera were able to react against E1 protein.
Conclusion:
Most of the assays showed immune reactivity against the DV or LV vaccine demonstrating the cross-reactive potential of such a vaccination approach. This cloning and immunization strategy based on the viral heterogeneity of the virus has in our view major implications for HCV, a virus with a broad viral genetic diversity, and may become in the future in the context of DNA- or viral-based vaccination strategies a possibility to overcome viral immune escape both in the prophylactic or therapeutic setting.
